Andrew Callos - 14 Mar 2025 Form 4 Insider Report for CYTOKINETICS INC (CYTK)

Role: EVP, Chief Commercial Officer
Signature: /s/ John O. Faurescu, attorney-in-fact for Mr. Callos
Issuer symbol: CYTK
Transactions as of: 14 Mar 2025
Transactions value $: $0
Form type: 4
Filing time: 18 Mar 2025, 16:20:45 UTC
Previous filing: 13 Mar 2025
Next filing: 17 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYTK	Common Stock	Award	$0	+32.7K	+86.79%	$0.00	70.4K	14 Mar 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYTK	Incentive Stock Option (Right to Buy)	Award	$0	+2.75K		$0.00	2.75K	14 Mar 2025	Common Stock	2.75K	$44.36	Direct	F2
transaction	CYTK	Non-Qualified Stock Option (Right to Buy)	Award	$0	+47.6K		$0.00	47.6K	14 Mar 2025	Common Stock	47.6K	$44.36	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Comprised of restricted stock units that convert to shares of common stock on a 1:1 basis upon vesting. 40% of the RSUs will vest on the 1-year anniversary of the date of grant; an additional 40% of the RSUs will vest on the 2-year anniversary of the date of grant; and the final 20% of the RSUs will vest on the 3-year anniversary of the date of grant, in each case subject to Mr. Callos's continued employment with the company on the scheduled vesting date.
F2	Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Callos's continued employment with the company on the scheduled vesting date.
F3	Stock options vest in equal monthly installments over 48 months from the date of grant, subject to Mr. Callos's continued employment with the company on the scheduled vesting date.